Table 1 Summary of responses seen in 26 patients with refractory hematological malignancies treated with haploidentical PBSC infusions [[15]]
From: Cellular immunotherapy for refractory hematological malignancies
| Malignancy | Complete response | Partial response | Transient response | Total response |
|---|---|---|---|---|
| AML | 3/13 (23%) | 0/13 (0%) | 7/13 (54%) | 10/13 (77%) |
| NHL | 2/6 (33%) | 2/6 (33%) | 0/6 (0%) | 4/6 (66%) |
